EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Rakuten Medical","sponsor":"The National Cancer Center Japan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Establishes Illuminox\u2122 Alliance Institutes to Accelerate Development of Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Closes Deal with Merck KGaA, Darmstadt to Receive Cetuximab for Production of its ASP-1929 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Rakuten Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Announces Acquisition of Medlight SA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakuten Medical Enrolls First Patient in the U.S. For ASP-1929 in Combination with Anti-PD1 Therapy, for Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakuten Medical Publishes Data from Phase I study of RM-1929 Photoimmunotherapy in Recurrent Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Momentum Capital Markets","pharmaFlowCategory":"D","amount":"$166.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical, Inc. Closes $166 Million Series D Financing led by General Catalyst","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Shimadzu","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakuten Medical and Shimadzu Enroll First Patient in the U.S. Clinical Trial of Photoimmunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform Cancer Treatment in the Middle East and North Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Rakuten Medical

    Menu

    Rakuten Medical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Rakuten Medical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa

              Details:

              Under the terms of the agreement, Hikma has an exclusive license to commercialize products in Rakuten Medical's pipeline using its photoimmunotherapy technology platform, Alluminox™, in all its MENA markets.

              Lead Product(s): Cetuximab Sarotalocan Sodium

              Therapeutic Area: Oncology Product Name: ASP-1929

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rakuten Medical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rakuten Medical and Shimadzu Enroll First Patient in the U.S. Clinical Trial of Photoimmunotherapy

              Details:

              The trial conducted for ASP-1929 photoimmunotherapy with fluorescence imaging, an antibody-dye conjugate binds to epidermal growth factor receptor, will assess efficacy and safety of surgical tumor resection in patients with operable primary or recurrent HNSCC or cuSCC.

              Lead Product(s): ASP-1929 Photoimmunotherapy

              Therapeutic Area: Oncology Product Name: ASP-1929

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Shimadzu

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rakuten Medical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rakuten Medical, Inc. Closes $166 Million Series D Financing led by General Catalyst

              Details:

              Rakuten Medical is conducting a global Phase 3 multi-center clinical trial with ASP-1929 IV Infusion (cetuximab sarotalocan sodium) in patients with recurrent head and neck squamous cell carcinoma.

              Lead Product(s): Cetuximab Sarotalocan Sodium

              Therapeutic Area: Oncology Product Name: Akalux

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Momentum Capital Markets

              Deal Size: $166.0 million Upfront Cash: Undisclosed

              Deal Type: Series D Financing July 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rakuten Medical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rakuten Medical Publishes Data from Phase I study of RM-1929 Photoimmunotherapy in Recurrent Head and Neck Squamous Cell Carcinoma

              Details:

              The data concluded that RM-1929 photoimmunotherapy showed a manageable safety profile in rHNSCC and showed tumor response in the heavily pre-treated patient population was clinically meaningful and warranted further investigation.

              Lead Product(s): Cetuximab-conjugated IRDye 700DX

              Therapeutic Area: Oncology Product Name: RM-1929

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rakuten Medical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rakuten Medical Enrolls First Patient in the U.S. For ASP-1929 in Combination with Anti-PD1 Therapy, for Head & Neck Cancer

              Details:

              The trial will enroll three cohorts of patients within distinct populations. Primary endpoints of this study include safety, tolerability, and tumor response of the ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy.

              Lead Product(s): Cetuximab-conjugated IRDye700DX,Pembrolizumab

              Therapeutic Area: Oncology Product Name: ASP-1929

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rakuten Medical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rakuten Medical Announces Acquisition of Medlight SA

              Details:

              IlluminoxTM technology platform developed ASP-1929 which binds to epidermal growth factor receptors (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck cancer, esophageal cancer, lung cancer, colon cancer, and pancreatic cancer.

              Lead Product(s): Cetuximab-conjugated IRDye700DX

              Therapeutic Area: Oncology Product Name: ASP-1929

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: Medlight SA

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition August 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rakuten Medical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rakuten Medical Closes Deal with Merck KGaA, Darmstadt to Receive Cetuximab for Production of its ASP-1929 Antibody-Drug Conjugate

              Details:

              Under this agreement, Rakuten Medical may use cetuximab to produce ASP-1929 for clinical trials and commercial sales.

              Lead Product(s): Cetuximab-conjugated IRDye700DX

              Therapeutic Area: Oncology Product Name: ASP-1929

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rakuten Medical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rakuten Medical Establishes Illuminox™ Alliance Institutes to Accelerate Development of Cancer Therapies

              Details:

              Under the signed MOU, NCC and Rakuten Medical will pursue multiple avenues to advance Illuminox-based cancer therapies. NCC will designate a lead principal who will act as an Illuminox Advisor.

              Lead Product(s): ASP-1929

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: The National Cancer Center Japan

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY